Madrigal Pharmaceuticals is a biotechnology company focused on developing new drugs for metabolic dysfunction associated with hepatic steatosis (MASH), a liver disease with a high unmet medical need.[1] The company's drug Rezdiffra (resmetirom) is a once-daily oral medication that targets the key causes of MASH through a liver-directed THR-β agonist.[1] In the six months ending on June 30, 2025, Madrigal's revenues increased from 14.6 million USD to 350.1 million USD.[1] The net loss fell by 61% to 115.5 million. USD.[1] The decrease in net loss was caused by the reduction of research and development expenses by 33% to 87.7 million. USD and by reducing interest expenses by 12% to 6.6 million. USD.[1] The company belongs to the field of biopharmaceuticals and medicines on MASH.[1]